SCHEMBL876113

SCHEMBL876113

Cc1cccn2c(=O)cc(Cl)nc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.52
MAPT P10636 3/20 0.52
NPSR1 Q6W5P4 2/20 0.52
RECQL P46063 1/20 0.52
ALDH1A1 P00352 6/20 0.49
GAA P10253 5/20 0.49
LMNA P02545 2/20 0.49
GLA P06280 2/20 0.49
MPI P34949 1/20 0.49
PKM P14618 1/20 0.48
HPGD P15428 4/20 0.45
PARP1 P09874 1/20 0.43
POLB P06746 2/20 0.42
HSD17B10 Q99714 3/20 0.42
PABPC1 P11940 1/20 0.42
CASP1 P29466 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11813953 0.83 KDM4E (0.69) KDM4EMAPTNPSR1RECQLALDH1A1
SCHEMBL8171222 0.80 KDM4E (0.42) KDM4EMAPTNPSR1RECQLALDH1A1
SCHEMBL3715566 0.80 KDM4E (0.65) KDM4EMAPTNPSR1RECQLALDH1A1
SCHEMBL875685 0.80 KDM4E (0.56) KDM4EMAPTNPSR1RECQLALDH1A1
SCHEMBL2149880 0.80 LMNA (0.42) KDM4EMAPTALDH1A1GAALMNA
SCHEMBL16175949 0.78 KDM4E (0.47) KDM4EMAPTNPSR1RECQLALDH1A1
SCHEMBL13833755 0.78 PKM (0.58) KDM4EMAPTALDH1A1GAALMNA
SCHEMBL1658643 0.76 ALDH1A1 (0.55) KDM4EMAPTNPSR1ALDH1A1GAA
SCHEMBL13833582 0.76 KDM4E (0.46) KDM4EMAPTNPSR1RECQLALDH1A1
SCHEMBL11805447 0.75 PKM (0.56) KDM4EMAPTALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2984093-B1 METAL COMPLEXES AND USE THEREOF IN ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2018-09-26 EP disclosed
US-20160308149-A1 Metal Complexes and Use Thereof in Electronic Devices MERCK PATENT GMBH (DE) 2016-10-20 US disclosed
EP-2984093-A1 METAL COMPLEXES AND USE THEREOF IN ELECTRONIC DEVICES Merck Patent GmbH (DE) 2016-02-17 EP disclosed
WO-2014166577-A1 METAL COMPLEXES AND USE THEREOF IN ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2014-10-16 WO disclosed
US-8785452-B2 Anti-infective compounds INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2014-07-22 US disclosed
US-8785452-B2 Anti-infective compounds INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2014-07-22 US disclosed
US-8785452-B2 Anti-infective compounds INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2014-07-22 US disclosed
EP-2730576-A2 Anti-infective compounds Institut Pasteur Korea (KR) 2014-05-14 EP disclosed
EP-2730576-A2 Anti-infective compounds Institut Pasteur Korea (KR) 2014-05-14 EP disclosed
EP-2619202-A1 PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES Pfizer Inc (US) 2013-07-31 EP disclosed
US-20130184294-A1 Pyrimidones for Treatment of Potassium Channel Related Diseases PFIZER INC. (US) 2013-07-18 US disclosed
US-20130012506-A1 ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES NO ZAESUNG (KR) 2013-01-10 US disclosed
US-20130012506-A1 ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES NO ZAESUNG (KR) 2013-01-10 US disclosed
US-20130012506-A1 ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES NO ZAESUNG (KR) 2013-01-10 US disclosed
WO-2012038850-A1 PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES PFIZER INC. (US) 2012-03-29 WO disclosed
US-20110178077-A1 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2011-07-21 US disclosed
US-20110178077-A1 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2011-07-21 US disclosed
US-20110178077-A1 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2011-07-21 US disclosed
WO-2011085990-A1 ANTI - INFECTIVE PYRIDO (1,2 -A) PYRIMIDINES INSTITUT PASTEUR KOREA (KR) 2011-07-21 WO disclosed
WO-2010003533-A2 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178077-A1 Anti-infective compounds RABGGTB, ELANE, SERPINB1 KDM4E 4439/4885MAPT 2660/4885NPSR1 4172/4885
US-20130012506-A1 ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES TYMS, TYMP, DCTPP1 KDM4E 4036/4885MAPT 2115/4885NPSR1 3987/4885
US-20160308149-A1 Metal Complexes and Use Thereof in Electronic Devices SOD1, SOD3, AP1M1 KDM4E 2991/4885MAPT 2034/4885NPSR1 3963/4885
US-20130184294-A1 Pyrimidones for Treatment of Potassium Channel Related Diseases KCNQ5, KCNQ1, KCNQ3 KDM4E 2185/4885MAPT 135/4885NPSR1 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.